← Back to Search

Anti-Beta Interferon for Dermatomyositis

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants aged ≥18 and ≤80 with moderate to severe dermatomyositis (DM), that have completed the treatment period of a qualifying study
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 12, 24, 36, 48 and 52
Awards & highlights

Study Summary

This trial will study the long-term effects of PF-06823859 in adults with DM.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are between 18 and 80 years old and have moderate to severe dermatomyositis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 12, 24, 36, 48 and 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, weeks 12, 24, 36, 48 and 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Clinically Significant Changes In Vital Signs
Incidence of Clinically Significant New Electrocardiogram (ECG) Findings
Incidence of Clinically Significant Treatment Emergent Laboratory Abnormalities
+1 more
Secondary outcome measures
Absolute Values and Change From Baseline of CDASI Damage Score
Absolute Values and Change From Baseline of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Scores
Change Over Time In the Health Assessment Quality of Life and Disability Index (HAQ-DI)
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Anti-Beta Interferon drug (PF-06823859)Experimental Treatment1 Intervention
IV infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Anti-Beta Interferon (PF-06823859)
2021
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,556 Previous Clinical Trials
10,907,658 Total Patients Enrolled
3 Trials studying Dermatomyositis
355 Patients Enrolled for Dermatomyositis
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,467 Previous Clinical Trials
8,089,095 Total Patients Enrolled
2 Trials studying Dermatomyositis
345 Patients Enrolled for Dermatomyositis

Media Library

Anti-Beta Interferon (PF-06823859) Clinical Trial Eligibility Overview. Trial Name: NCT05192200 — Phase 2
Dermatomyositis Research Study Groups: Anti-Beta Interferon drug (PF-06823859)
Dermatomyositis Clinical Trial 2023: Anti-Beta Interferon (PF-06823859) Highlights & Side Effects. Trial Name: NCT05192200 — Phase 2
Anti-Beta Interferon (PF-06823859) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05192200 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the eligibility criteria of this trial restricted to individuals over 55 years old?

"The primary requirement for entry in this experiment is to be over 18 and under 80 years old."

Answered by AI

Are there any open enrolment slots in the current trial?

"According to the clinicaltrials.gov records, this medical trial is no longer recruiting patients--the original posting was on December 20th 2021 and it last edited November 17th 2022. Fortunately, there are currently 23 other trials actively seeking participants."

Answered by AI

Has the FDA granted approval for Anti-Beta Interferon (PF-06823859)?

"Our team at Power determined that the safety of Anti-Beta Interferon (PF-06823859) should be rated as a 2, due to having some existing evidence in favor of its security, but lacking any concerning efficacy."

Answered by AI

How extensive is the geographic coverage of this research endeavor?

"This clinical research is enrolling patients in KU Clinical and Translational Science Unit (CTSU) Rainbow located in Scottsdale, Arizona; Mayo Clinic found in New york City; Mount Sinai Doctors Dermatology situated near Boston, Massachusetts as well as other 23 sites."

Answered by AI

What criteria must be met to qualify for participation in this trial?

"To be eligible, candidates must suffer from dermatomyositis and fall within the age range of 18 to 80. The trial is looking for 24 individuals in total."

Answered by AI
~7 spots leftby Mar 2025